Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923091 | 0.75 | APLNR (0.38) | APLNRAAK1DGAT1 | |
| SCHEMBL1145058 | 0.73 | GABRA1 (0.39) | APLNRDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL7268898 | 0.72 | CYP1A2 (0.37) | — | |
| SCHEMBL15332748 | 0.72 | PDE2A (0.44) | APLNRDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL360836 | 0.71 | APLNR (0.40) | APLNRAAK1 | |
| SCHEMBL24633625 | 0.70 | DGAT1 (0.35) | DGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL2961939 | 0.70 | DGAT1 (0.35) | DGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL4930943 | 0.70 | AAK1 (0.40) | APLNRAAK1DGAT1 | |
| SCHEMBL182595 | 0.69 | PDE2A (0.47) | DGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL12261433 | 0.69 | GABRA1 (0.46) | APLNRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | APLNR 3357/4885BACE1 2807/4885AAK1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.